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http://dx.doi.org/10.1016/j.numecd.Abstract Background and aims: Metformin is the first-line therapy in type 2 diabetes. In
patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglita-
zone are equally plausible options to improve glycemic control. However, these drugs have
profound differences in their mechanism of action, side effects, and impact on cardiovascular
risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity
and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pio-
glitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately
controlled with metformin.of Clinical and Experimental Medicine, “Federico II” University of Naples, Via S. Pansini 5, 80131
ax: þ39 0815466152.
(O. Vaccaro).
2 Elsevier B.V. All rights reserved.
2012.09.003
998 O. Vaccaro et al.Methods: Multicentre, randomized, open label, parallel group trial of 48 month duration. Type
2 diabetic subjects, 50e75 years, BMI 20e45 Kg/m2, on secondary failure to metformin mono-
therapy will be randomized to add-on a sulfonylurea or pioglitazone. The primary efficacy
outcome is a composite endpoint of all-cause mortality, nonfatal myocardial infarction,
nonfatal stroke, and unplanned coronary revascularization. Principal secondary outcome is
a composite ischemic endpoint of sudden death, fatal and non-fatal myocardial infarction
and stroke, endovascular or surgical intervention on the coronary, leg or carotid arteries,
major amputations. Side effects, quality of life and economic costs will also be evaluated. Effi-
cacy, safety, tolerability, and study conduct will be monitored by an independent Data Safety
Monitoring Board. End points will be adjudicated by an independent external committee.
Conclusions: TOSCA.IT is the first on-going study investigating the head-to-head comparison of
adding a sulfonylurea or pioglitazone to existing metformin treatment in terms of hard cardio-
vascular outcomes.
Registration: Clinicaltrials.gov ID NCT00700856.
ª 2012 Elsevier B.V. All rights reserved.Introduction
There is general agreement that metformin, if not contra-
indicated and well tolerated, should be the first agent in
the treatment of type 2 diabetes [1e5], but considerable
uncertainty does exists on the best therapeutic option as
second line treatment after metformin failure. According
to recent guidelines, in patients inadequately controlled
with metformin, the addition of a sulfonylurea (SU) or
pioglitazone are equally plausible options to improve gly-
cemic control [6,7]. However, these two drugs have
profound differences in their mechanisms of action, side
effects, and impact on cardiovascular (CV) risk factors.
SUs have been available for a long time and are the least
expensive and more widely used oral hypoglycemic agents.
They stimulate insulin secretion by binding the ATP-sensitive
potassium channels in the beta cells. SUs rapidly lower blood
glucose, but are associated with modest weight gain,
increased risk of hypoglycaemia and a secondary failure rate
that exceeds other drugs [8]. In addition, the CV effects of
SUs are debated. These agents bind to various degrees the
ATP channels in the cardiomyocytes thus blunting the
myocardial preconditioning mechanism [9,10]. To what
extent thismay impact CVmorbidity andmortality is unclear.
Observational studies report higher all-cause and CV
mortality with SUs vs. metformin monotherapy [11e16] and
in case series of coronary angioplasty, patients on SUs had
higher in-hospital mortality than patients on other treat-
ments [17]. To the contrary, data from the French registry on
Acute ST and non ST-elevation Myocardial Infarction (FAST-
MI) have shown a better outcome in patients on SUs at
admission as compared with patients on other treatments
[18]. As for intervention studies, in the University Group
Diabetes Program (UGDP) [19] patients receiving tolbutamide
experienced more CV events than those treated with insulin,
whereas in the UKPDS there is no evidence of an adverse
effect of SUs on CVD outcomes [20] and more recently, in the
Action in Diabetes and Vascular Disease: Preterax and
Diamicron-MR Controlled Evaluation (ADVANCE) study,
intensive therapy with gliclazide significantly reduced the
risk of microvascular endpoint, with no detrimental effects
on macrovascular events [21]. The thiazolidinediones (TZDs)are insulin sensitizing agents [22]: they lower blood glucose
without causing hypoglycaemia and provide more durable
glycemic effect than other drugs [8]. Pioglitazone also
improves lipid profile, blood pressure, albuminuria, and
inflammatory and procoagulant markers, an array of effects
which may translate into better CV outcomes. Furthermore
the PROACTIVE (PROspective pioglitAzone Clinical Trial In
macroVascular Events) study has shown that the addition of
pioglitazone to the hypoglycaemic therapy in patients with
type 2 diabetes and overt macrovascular disease significantly
reduced a composite end point of all-cause mortality,
nonfatal MI and stroke as compared to placebo [23]. In
addition the CHICAGO and PERISCOPE studies have shown
that pioglitazone, as comparedwith glimepiride, reduces the
progression of carotid intimaemedia thickness [24] and the
progression of intracoronary atherosclerosis [25]. Recognized
side effects of pioglitazone, which may restrain a more
common use, include unwanted weight gain, fluid retention
leading to edema and/or heart failure in predisposed indi-
viduals, increased risk of bone fractures and possibly bladder
cancer [26,27].
Due to the paucity of experimental evidence, the algo-
rithms for managing glycemia recommended by the several
professional associations and scientific societies are largely
based on the opinion of experts and are not fully concor-
dant [1e7]. In particular, the CVD effects of glucose-
lowering agents remain debated. The Thiazolidinediones
Or Sulphonylureas and Cardiovascular Accidents. Interven-
tion Trial (TOSCA.IT) study was designed and initiated to
compare the effects of the addition of SUs vs. pioglitazone
on CV events in patients with type 2 diabetes inadequately
controlled with metformin monotherapy. Durability of
glucose control, side effects, quality of life and costs will
also be evaluated.Methods
Research design
The study (protocol number FARM6T9CET), registered in the
clinicaltrials.gov with ID NCT00700856, is a multicentre,
Pioglitazone or sulphonylureas and CV events in type 2 diabetes 999parallel-group trial of 48 months duration. A Prospective
Randomized Open Blinded End-Point Evaluation (PROBE)
design is employed. The protocol has been approved by the
Ethics Review Committee/Insitutional Review Board of the
Coordinating Centre and of each participating centre. The
study is carried out in accordance with the Declaration of
Helsinki and the Good Clinical Practice guidelines. Written
informed consent must be obtained from participants
before beginning any protocol-specific procedure and the
participants are informed of their right to withdraw from
the study at any time. Standard procedures for assuring full
respect of privacy are undertaken. The conduct of each
participating center is monitored by regular visits of
professional monitors.
Efficacy end points
The primary efficacy outcome is a composite of all-cause
mortality, nonfatal myocardial infarction (MI) (including
silent MI), nonfatal stroke, unplanned coronary revascu-
larization. The principal secondary outcome is a composite
ischemic end point of sudden death, fatal and non-fatal MI
(including silent MI), fatal and nonfatal stroke, major leg
amputation (above the ankle), endovascular or surgical
interventions on the coronary, leg or carotid arteries.
Other secondary outcomes are:
1) A composite CV endpoint including the primary
endpoint plus hospitalization for heart failure, endo-
vascular or surgical intervention on the coronary, leg or
carotid arteries, incident angina or intermittent
claudication;
2) All cases of heart failure;
3) A microvascular composite endpoint including: incident
macroalbuminuria, or doubling of baseline plasma
creatinine, or a creatinine clearance reduction of
20 ml/min/1.73 m2 or plasma creatinine >3.3 mg/dl, or
dialysis;Table 1 Overview of inclusion/exclusion criteria.
Inclusion criteria Ex
- Type 2 diabetes of at least 2 years duration
- Males and females, age 50e75 years
- BMI 20e45 Kg/m2
- Stable treatment for the last two
months with metformin in
monotherapy at 2 g/day
- HbA1c  7.0% and 9.0%
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BMI: body mass index; HbA1c: glycated hemoglobin; SUs: sulfonylure
ALT: Alanine aminotransferase.4) Glucose control (changes from baseline in HbA1c, time
to failure of oral hypoglycaemic therapy, defined as
HbA1c >8.0% on two occasions three months apart);
5) Changes from baseline of the CV risk factors profile
(lipids, blood pressure, microalbuminuria, inflamma-
tion markers, waist circumference).
A Clinical Endpoints Committee (CEC) of expert clini-
cians (cardiologists, diabetologists, internal medicine
specialists and epidemiologists), blind to study medication
assignment, is reviewing and adjudicating the outcomes
included in the primary endpoint plus all the cases of heart
failure and revascularization according to predefined
criteria.
Visits and procedures
The eligibility criteria are listed in Table 1. Eligible patients
are randomized to one of two treatments (Fig. 1):
metformin þ sulfonylurea (glibenclamide 5 mg or gliclazide
30 mg or glimepiride 2 mg used according to local practice)
or metformin þ pioglitazone (15 mg). Treatment is cen-
trally assigned by telephone after verification of eligibility.
The treatment allocation schedule is computer generated
in blocks and stratified according to centre and previous CV
events. The investigators are masked to the randomization
sequences.
An outline of the study procedures is given in Table 2. At
screening the study aims and procedures are extensively
discussed with the patients, a written informed consent is
obtained and the inclusion/exclusion criteria are assessed.
Patients deemed eligible and willing to participate are
enrolled. At baseline (randomization visit) the inclusion/
exclusion criteria are reassessed, a complete medical
history, including prior CV events and use of medications, is
recorded; a complete physical examination, including
standardised measurements of blood pressure, body
weight, height, waist and hip circumference and a standardclusion criteria
ype 1 diabetes
revious treatment with TDZs within the last six months
ontraindication/intolerance to metformin or SUs or TZDs
ocumented coronary or cerebrovascular events within
he previous 3 months
erum creatinine > 1.5 mg/dl
istory of congestive heart failure, NYHA class I or higher
hronic use of glucocorticoids
schemic ulcer or gangrene of lower extremities
iver cirrhosis or severe hepatic dysfunction (ALT > 2.5 times
he upper normal limit)
regnancy or breast feeding
ancer, substance abuse, or any health problem that may
nterfere with the compliance to the study protocol or limit
ife expectancy
as; TZDs: thiazolidinediones; NYHA: New York Heart Association;
Table 2 Overview of the study assessments.
Visit Screening Baseline Year 1 Years 2e4
1 mo 3 mo 6 mo 12 mo Semiannually Annually
Inclusion/exclusion
criteria assessment
x x
Informed consent obtainment x
Clinical history x x x x x x x x
Anthropometry x x x x x x x x
Clinical examination x x x x x x x x
ECG x x x
Food frequency questionnaire x x x
Quality of life questionnaire x x x
Economic questionnaire x x x
Biochemistry
HbA1c x x x x x
Lipids x x x
Creatinine x x x
Microalbuminuria x x x
PCR x x x
Urinalysis and assessment
of hematuriaa
x x x x x
Hypoglycaemia x x x x x x x
Compliance x x x x x x x
Endpoint events x x x x x x x
Adverse events x x x x x x x
Plasma lipids include: total cholesterol, HDL cholesterol and triglycerides.
a Starting from January 2012.
1000 O. Vaccaro et al.12-lead ECG, is performed. Fasting blood samples and
a morning spot urine sample are collected for biochemical
analyses (see Table 2). Dietary habits are assessed using
a validated food frequency questionnaire e the Italian
version of the European Prospective Investigation into
Cancer and Nutrition (EPIC) questionnaire. Quality of lifeScreening visit:
Eligibility assessment and informed consent 
obtainment
Randomization
Metformin 2 gr/day
+
Pioglitazone 15 mg/day
Metformin 2 gr/day
+
Sulfonylurea: 
glibenclamide 5 mg/day or 
gliclazide R.M. 30 mg/day or
glimepiride 2 mg/day
Follow-up visits at 1, 3 and 6 months from randomization. 
Semiannually thereafter for at least 48 months
Figure 1 Flow chart of the study design.and economic costs will also be assessed with the use of
standard questionnaires. All participants are instructed to
perform home glucose monitoring (one full day glucose
profile per week) and to record the number and severity of
hypoglycaemic events.
Follow-up is scheduled at 1, 3, and 6 months after
randomization and biannually thereafter (Table 2). At each
visit adherence to the study protocol is assessed, informa-
tion on the occurrence of any adverse or endpoint event(s)
is collected. Anthropometry, blood pressure and heart rate
are measured. Since January 2012, due to regulatory
concerns regarding pioglitazone and the risk of bladder
cancer, macroscopic hematuria is also assessed at each
visit. HbA1c is measured semiannually. A standard 12-lead
ECG, fasting plasma lipids (total cholesterol, HDL choles-
terol, triglycerides), creatinine, high sensitivity C-reactive
protein (hsCRP), and urinary excretion of albumin and
creatinine are performed annually. The patient’s home
glucose readings and the records of hypoglycaemia are
reviewed at each visit. The metformin dose remains
constant (2 g/day) throughout the study. The add-on drugs
will be up-titrated at any follow-up visit, if necessary,
based on home glucose monitoring (i.e fasting glucose
>120 mg/dl or post prandial glucose >160 mg/dl in more
than 50% of the home glucose readings performed over the
last 8 weeks period). The maximum daily dose is 15 mg for
glibenclamide, 120 mg for gliclazide, 6 mg for glimepiride,
and 45 mg for pioglitazone. If, despite the maximal daily
dose of the drugs has been reached, blood glucose control is
still unsatisfactory, adherence to treatments is assessed,
lifestyle recommendations are reinforced and HbA1c is re-
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will lead to add on a bed-time injection of basal insulin
(glargine) and prandial rapid acting insulin boluses, if
glucose control is still unsatisfactory. Insulin titration is
performed according to a pre-defined algorithm based on
self-monitored fasting capillary glucose [28].
Concomitant medications are allowed throughout the
study. Initiation and dose adjustments of antihypertensive,
lipid-lowering and antiplatelet agents are made according
to current guidelines [7] and clinical judgment. The trade
name and dosage of all medications are recorded at each
visit. Ad hoc developed electronic Case Report Forms
(CRFs) are used for data collection, data is web-transmitted
to the Data Monitoring Centre where the forms are checked
for missing or incoherent data. An electronic data base is
being created using a standardized procedure for data
input.
Laboratory measurements
A fasting blood sample is obtained in the morning, imme-
diately centrifuged and serum is aliquoted; a spot urine
sample is also collected and aliquoted. The samples are
transferred within two days, under appropriate conditions,
to the central laboratory and processed on arrival. Extra
samples are stored (80 C) for future analyses. Glycated
hemoglobin is measured by HPLC (ion-exchange chroma-
tography) using an automatic analyzer (Adams A1c HA-8160,
Menarini). Lipids, plasma and urine creatinine, and albu-
minuria are measured on the automatic analyzer MODULAR
SWA (Roche Diagnostics, Italy) respectively by enzymatic-
colorimetric methods, ECLIA and immunoturbidimetry.
CRP is determined by a high sensitive immunonephelo-
metric method (CardioPhase hs CRP, SIEMENS) on the BN II
System (SIEMENS). Brain Natriuretic peptide (NT-proBNP)
can be measured centrally at any time, according to the
researchers judgment, in case signs or symptoms suggestive
of heart failure develop. Any other test judged useful from
the clinical stand point is performed at each centre.
Safety assessment
The study drugs are largely used for the treatment of dia-
betes, no additional risk, besides the known side effects of
the drugs, is envisaged. The occurrence of adverse events
(hypoglycaemic events, weight gain, peripheral edema,
heart failure episodes, etc.) is strictly monitored. Hypo-
glycaemia is defined as a documented glucose value lower
than 60 mg/dl and graded as moderate (not requiring help
for treatment) or severe (requiring assistance for treatment
or associated with loss of consciousness or requiring
glucagon or endovenous glucose for treatment).
Patients will stop the study medications if any of the
followings occurs: alanine amino transferase increases
three times from baseline on two consecutive occasions,
one month apart; heart failure, evaluated according to the
American Heart Association and the American Diabetes
Association consensus on glitazones and heart failure [29],
or any other medical condition(s) that contraindicates the
use of the study medication(s). In addition, in the piogli-
tazone arm, treatment will be withdrawn if macroscopichematuria of unknown origin occurs at any time or bladder
cancer is diagnosed. Patients who are withdrawn from the
study medications enter a follow-up observational period
following the scheduled protocol visits. An external Data
Safety and Monitoring Board (DSMB) will monitor safety
throughout the study and review the critical efficacy
endpoints.
Pharmacoeconomic evaluation
The health status and pharmacoeconomic outcomes are
assessed by a standard questionnaire (EQ 5D 5 levels).
Direct and indirect costs of the two treatment regimens will
be evaluated; the cost-effectiveness analysis (CEA), cost-
consequence analysis (CCA) and cost-minimization analysis
(CMA) will be conducted as appropriate.
Sample size estimation
The sample size is estimated to detect a reduction in the
risk of events of 20% (HRZ 0.80; metformin þ pioglitazone
vs. metformin þ SU) with a statistical power of 80% and
a p < 0.05, one tail. The estimated occurrence rate of the
primary end point is 3.5% per annum [30e32] and the
estimated loss to follow-up is 5%. The efficacy analysis will
be event driven. Given these assumptions, a total of 3371
patients will be enrolled and a total of 498 events have to
be reached to complete the study. The planned follow-up is
4 years; however results of recent trials have shown that
the rate of occurrence of the primary end point may
actually be lower than we anticipate, therefore a longer
follow-up may be necessary to reach the needed number of
events.
Statistical analysis
The trial is event driven and the efficacy analysis will be
conducted according to intention to treat. Based on the
number of occurring events, individual components of the
primary and secondary composite endpoint will also be
analysed.
Incidence rates will be evaluated using KaplaneMeier
survival curves that will be compared (metformin þ
pioglitazone vs. metformin þ SU) using logrank analysis.
Treatment efficacy will be assessed by multivariate anal-
yses using Cox’s regression.
Other secondary analyses will include the evaluation of
efficacy of metformin þ pioglitazone vs. metformin þ SU on
pre-defined secondary end-points. Side effects, direct and
indirect costs will also be compared in the two study arms.
Incidence and severity of hypoglycaemia will be compared
between arms using a Poisson regression model. Subgroups
analyses will be performed according to gender, BMI and
prior cardiovascular events.
Organizational characteristics
The study is conducted at Diabetes Clinics by diabetes
specialists (a complete list of the study participants is re-
ported in Appendix). More than one hundred clinics
distributed all over Italy are currently participating in the
Table 3 General characteristics of the study participants
(n Z 2450).
M  SD or n (%)
Age 62.8  6.6
Males n (%) 1318 (57.4)
BMI (kg/m2) 30.3  4.4
Waist circumference (cm) 104.3  11.1
Diabetes duration (years) 8.6  5.8
HbA1c% 7.7  0.5
Total cholesterol (mmol/l) 4.68  0.95
HDL cholesterol (mmol/l) 1.20  0.37
LDL cholesterol (mmol/l) 2.69  0.82
Triglycerides (mmol/l) 1.74  0.94
Systolic blood pressure (mmHg) 134.2  14.9
Diastolic blood pressure (mmHg) 79.7  8.5
Microalbuminuria 467 (20)
Antihypertensive treatment 1567 (68)
Antiplatelet treatment 953 (42)
Hypolipidemic treatment 1280 (56)
Prior CV event(s) 238 (10.4)
1002 O. Vaccaro et al.study. Screening and follow-up visits are performed
according to a standard protocol described in detail in the
manual of operation (MOP). Prior to the initiation of the
study, the investigators attended training and standardi-
zation sessions in order to minimize inter-observer
variability.
The Coordinating Centre is based at the Department of
Clinical and Experimental Medicine of the “Federico II”
University of Naples, Italy, and is responsible for the
preparation of the study protocol, the Manual of Operations
(MOP) and the organization of the training sessions for the
field investigators.
The Centre for the Data Monitoring and Randomization,
based at the Consorzio Mario Negri Sud in Santa Maria Imbaro
(CH), provides a centralized telephone randomization
system for the patients allocation to study medications, and
is responsible for data management and analyses.
The ECG reading will be performed at the Centro Studi
ANMCO in Florence by certified readers blinded to treat-
ment arm and according to a standard protocol.
The biochemical analyses are performed at the Depart-
ment of Laboratory Medicine, Desio Hospital, Monza-
Brianza, Italy.
The food frequency questionnaire is produced and elec-
tronically read at REGGIANI S.p.A., Varese, Italy; nutrients,
food groups, glycemic index, glycemic load and oxidative
capacity will be calculated at the Nutritional Epidemiology
Unit of the Department of Preventive & Predictive Medicine,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, with
the use of an ad hoc developed software.
The Pharmacoeconomic and Pharmacovigilance Units
are based at the “Federico II” University of Naples, Italy.
Preliminary data
To date 2450 patients have been enrolled (i.e. 73% of the
total sample required). End of recruitment is planned within
June 2013. The general characteristics of the participants
are given in Table 3. Overall they are middle aged, obese,
with a mean diabetes duration of 8.6  5.8 years, a mean
HbA1c of 7.7  0.5%. On average, lipids and blood pressure
are well controlled; 56% are on lipid lowering drugs, 68%
report taking antihypertensive medications, 42% use anti-
platelet medications and 10.4% report a prior CV event.
Discussion
In clinical practice, the beneficial effects of the various
hypoglycaemic treatments must be considered not only in
relation to their glucose lowering effects (reduction of
HbA1c, time to failure of glucose control), but also in
relation to their impact on the risk for the long term
complications of diabetes. In addition the benefits have to
be balanced against safety (drug-specific side effects, risk
of hypoglycaemias, effects on body weight, etc.).
So far, no study has provided a direct (head to head)
comparison of different anti-diabetic drugs on long term
complications. As a consequence, the several compounds
(SUs, pioglitazone, glinides, DPP-4 inhibitors, etc.) have
been indicated by current guidelines and expert recom-
mendations as equally plausible options when metforminmonotherapy fails, despite the fact that mechanisms of
action are different, durability is not superimposable, safety
profile and costs are not identical [6,7].
Comparative effectiveness research, particularly with
regard to CV outcomes, has a high priority in order to allow
evidence based medical decisions, improve public health
and optimize cost effectiveness in the management of type
2 diabetes.
The Thiazolidinediones Or Sulphonylureas and Cardio-
vascular Accidents. Intervention Trial (TOSCA.IT study) is
the first trial designed as a head-to-head comparison of two
hypoglycaemic strategies on CV endpoints and is also the
only ongoing study that evaluates the potential benefits of
TZDs on cardiovascular disease, as the TIDE (Thiazolidine-
dione Intervention With Vitamin D Evaluation) has been
terminated prematurely owing to concerns on the CV safety
of rosiglitazone [33].
The TOSCA.IT study will also shed light on other relevant
issues, such as glucose-lowering effects, time to failure of
oral hypoglycaemic therapy, quality of life, side effects and
economic costs, including the costs of adverse effects,
particularly hypoglycaemia. This information is lacking and
is strongly needed to allow an evidence based choice for
the management of type 2 diabetes.
Funding
The study is supported by the Italian Medicines Agency
(AIFA) within the Independent Drug Research Program e
contract no. FARM6T9CET and by Diabete Ricerca, the no
profit Research Foundation of the Italian Diabetes Society
(SID).
Duality of interest
O Vaccaro, M Masulli, A Nicolucci, CB Giorda, P Mocarelli, S
Squatrito, AA Rivellese and G Riccardi declare that they
have no duality of interest associated with this manuscript.
Pioglitazone or sulphonylureas and CV events in type 2 diabetes 1003E Bonora is a member of the Italian Takeda Advisory Board
and has received a research grant from Takeda in the last 2
years. S Del Prato has served on advisory panels for Novartis
Pharmaceuticals, Merck & Co., Roche Pharmaceuticals, Eli
Lilly and Co., Boehringer Ingelheim, Novo Nordisk, Takeda
Pharmaceuticals, Intarcia Therapeutics Inc., and Astra
Zeneca and, as speaker from Novartis, Sanofi-aventis, Eli
Lilly and Co. and Bristol-Myers Squibb. Research support
was funded by Merck&Co., Novo Nordisk, Takeda Pharma-
ceuticals, Novartis Pharmaceuticals. AP Maggioni is
a member of the Steering Committee of trials sponsored by
SanofieAventis and Eli Lilly.
Contribution statement
Vaccaro, M Masulli, E Bonora, S Del Prato, AA Rivellese, S
Squatrito, G Riccardi were involved in the conception and
design of the study protocol, drafting of the article and
final approval of the version to be published. A Nicolucci
was involved in the design of the study and was responsible
for data analysis. CB Giorda, AP Maggioni, P Mocarelli
revised the manuscript critically providing important
intellectual content and final approval of the version to be
published.
Appendix A
Executive Committee: Gabriele Riccardi, Federico II
University of Naples, Italy; Enzo Bonora, University of Ver-
ona, Italy; Stefano Del Prato, University of Pisa, Italy; Carlo
B. Giorda, ASL Torino 5, Turin Italy; Aldo Pietro Maggioni,
ANMCO Research Center, Florence, Italy; Paolo Mocarelli,
Desio Hospital, Monza-Brianza, Italy; Antonio Nicolucci,
Consorzio Mario Negri Sud, S. Maria Imbaro (CH), Italy;
Angela A. Rivellese, Federico II University of Naples, Italy;
Sebastiano Squatrito, Garibaldi-Nesima Hospital, Catania,
Italy; Olga Vaccaro, Federico II University of Naples, Italy.
Coordinating Center: Olga Vaccaro, Maria Masulli, Nadia
Garofalo, Federico II University of Naples, Italy. Data Safety
Monitoring Board. Committee Members: Eleuterio Ferran-
nini (Chair), Universita` di Pisa, Italy; Barbara Howard,
Medstar Research Institute, Washington, USA; Eva Gerdts,
University of Bergen, Norway; Giuseppina Imperatore, CDC,
Atlanta, USA; Luigi Tavazzi, GVM Care&Research, Cotignola
(RA), Italy; Fabio Pellegrini,Consorzio Mario Negri Sud, S.
Maria Imbaro, (CH) Italy. Clinical Event Committee. Gianna
Fabbri (Coordinator), Centro Studi ANMCO, Florence, Italy;
Giacomo Levantesi (Cardiologist), Ospedale San Pio da
Pietralcina, Vasto; Fabio Turazza (Cardiologist), Ospedale
Niguarda Ca’ Grande di Milano; Sandro Gentile (Diabetol-
ogist), Second University of Naples, Italy; Salvatore Panico
(Internist), Federico II University of Naples, Italy; Massimo
Porta (Internist), Ospedale Le Molinette, University of
Torino, Italy.
Central Laboratory. Paolo Mocarelli, Paolo Brambilla,
Stefano Signorini, Fabrizio Cappellini, Chiara Parma,
Department of Laboratory Medicine, Desio Hospital, Monza-
Brianza, Italy. Data managing. Antonio Nicolucci, Daniela
D’Alonzo, Barbara Di Nardo, Sonia Ferrari, Monica Fran-
ciosi, Romina Pecce, Miriam Valentini. Consorzio Mario
Negri Sud, S. Maria Imbaro, (CH) Italy.On site monitoring. Martina Ceseri, Francesca Bianchini,
Ester Baldini, Antonio Atzori. ANMCO Research Center, Flor-
ence, Italy.
Participating centers
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Massimo Boemi. Co-investigators: Federica D’Angelo, Rob-
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Paolo Di Berardino. Co-investigator: Emanuela Cannarsa
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Investigator: Roberto Trevisan. Co-investigator: Cristiana
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